6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Cardiovascular B-OSE_Labeled_AE
Thrombotic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
GI B-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
, O
Ulceration O
and O
Perforation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Heart B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
and O
Edema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Renal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
and O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Anaphylactic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Serious O
Skin B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
with O
PENNSAID O
are O
application O
site O
reactions O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Horizon O
Pharma O
USA O
Inc O
. O
at O
1-866-479-6742 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
PENNSAID O
of O
130 O
patients O
treated O
for O
4 O
weeks O
( O
mean O
duration O
of O
28 O
days O
) O
in O
one O
Phase O
2 O
controlled O
trial O
. O

This O
population O
's O
mean O
age O
was O
approximately O
60 O
years O
, O
85 O
% O
of O
patients O
were O
Caucasian O
, O
65 O
% O
were O
females O
, O
and O
all O
patients O
had O
primary O
osteoarthritis B-Not_AE_Candidate
. O

The O
most O
common O
adverse O
events O
with O
PENNSAID O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

These O
events O
were O
the O
most O
common O
reason O
for O
withdrawing O
from O
the O
study O
. O

Application O
Site O
Reactions O
: O
In O
this O
controlled O
trial O
, O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
characterized O
by O
one O
or O
more O
of O
the O
following O
: O
dryness O
( O
22 O
% O
) O
, O
exfoliation O
( O
7 O
% O
) O
, O
erythema O
( O
4 O
% O
) O
, O
pruritus O
( O
2 O
% O
) O
, O
pain O
( O
2 O
% O
) O
, O
induration O
( O
2 O
% O
) O
, O
rash O
( O
2 O
% O
) O
, O
and O
scabbing O
( O
< O
1 O
% O
) O
. O

Other O
Common O
Adverse O
Reactions O
: O
Table O
1 O
lists O
all O
adverse O
reactions O
occurring O
in O
> O
1 O
% O
of O
patients O
receiving O
PENNSAID O
, O
where O
the O
rate O
in O
the O
PENNSAID O
group O
exceeded O
vehicle O
, O
from O
a O
controlled O
study O
conducted O
in O
patients O
with O
osteoarthritis B-Not_AE_Candidate
. O

Table O
1 O
: O
Incidence O
of O
Adverse O
Reactions O
Occurring O
in O
> O
1 O
% O
of O
Subjects O
with O
Osteoarthritis O
Using O
PENNSAID O
and O
More O
Often O
than O
in O
Subjects O
with O
OA O
Using O
Vehicle O
Control O
( O
Pooled O
) O
Adverse O
Reaction O
PENNSAIDN=130n O
( O
% O
) O
Vehicle O
ControlN=129n O
( O
% O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
4 O
( O
3 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
induration I-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Contusion B-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
1 O
( O
< O
1 O
% O
) O
Nausea B-OSE_Labeled_AE
2 O
( O
2 O
% O
) O
0 O
PENNSAID O
1.5 O
% O
The O
safety O
of O
PENNSAID O
2 O
% O
is O
based O
in O
part O
, O
on O
prior O
experience O
with O
PENNSAID O
1.5 O
% O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
PENNSAID O
1.5 O
% O
of O
911 O
patients O
treated O
between O
4 O
and O
12 O
weeks O
( O
mean O
duration O
of O
49 O
days O
) O
in O
seven O
Phase O
3 O
controlled O
trials O
, O
as O
well O
as O
exposure O
of O
793 O
patients O
treated O
in O
an O
open-label O
study O
, O
including O
463 O
patients O
treated O
for O
at O
least O
6 O
months O
, O
and O
144 O
patients O
treated O
for O
at O
least O
12 O
months O
. O

The O
population O
mean O
age O
was O
approximately O
60 O
years O
, O
89 O
% O
of O
patients O
were O
Caucasian O
, O
64 O
% O
were O
females O
, O
and O
all O
patients O
had O
primary O
osteoarthritis B-Not_AE_Candidate
. O

The O
most O
common O
adverse O
events O
with O
PENNSAID O
1.5 O
% O
were O
application B-OSE_Labeled_AE
site I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

These O
events O
were O
the O
most O
common O
reason O
for O
withdrawing O
from O
the O
studies O
. O

Application O
Site O
Reactions O
: O
In O
controlled O
trials O
, O
application B-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
were O
characterized O
by O
one O
or O
more O
of O
the O
following O
: O
dryness O
, O
erythema O
, O
induration O
, O
vesicles O
, O
paresthesia O
, O
pruritus O
, O
vasodilation O
, O
acne O
, O
and O
urticaria O
. O

The O
most O
frequent O
of O
these O
reactions O
were O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
( O
32 O
% O
) O
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
characterized O
by O
skin B-NonOSE_AE
erythema I-NonOSE_AE
and O
induration B-NonOSE_AE
( O
9 O
% O
) O
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
with I-OSE_Labeled_AE
vesicles I-OSE_Labeled_AE
( O
2 O
% O
) O
and O
pruritus O
( O
4 O
% O
) O
. O

In O
one O
controlled O
trial O
, O
a O
higher O
rate O
of O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
with I-OSE_Labeled_AE
vesicles I-OSE_Labeled_AE
( O
4 O
% O
) O
was O
observed O
after O
treatment O
of O
152 O
subjects O
with O
the O
combination O
of O
PENNSAID O
1.5 O
% O
and O
oral O
diclofenac O
. O

In O
the O
open-label O
uncontrolled O
long-term O
safety O
study O
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
occurred O
in O
13 O
% O
and O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
with I-OSE_Labeled_AE
vesicles I-OSE_Labeled_AE
in O
10 O
% O
of O
patients O
, O
generally O
within O
the O
first O
6 O
months O
of O
exposure O
, O
leading O
to O
a O
withdrawal O
rate O
for O
an O
application O
site O
event O
of O
14 O
% O
. O

Other O
Common O
Adverse O
Reactions O
: O
In O
controlled O
trials O
, O
subjects O
treated O
with O
PENNSAID O
1.5 O
% O
experienced O
some O
adverse O
events O
associated O
with O
the O
NSAID O
class O
more O
frequently O
than O
subjects O
using O
placebo O
( O
constipation B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
; O
see O
Table O
2 O
) O
. O

The O
combination O
of O
PENNSAID O
1.5 O
% O
and O
oral O
diclofenac O
, O
compared O
to O
oral O
diclofenac O
alone O
, O
resulted O
in O
a O
higher O
rate O
of O
rectal B-NonOSE_AE
hemorrhage I-NonOSE_AE
( O
3 O
% O
vs O
. O
less O
than O
1 O
% O
) O
, O
and O
more O
frequent O
abnormal B-NonOSE_AE
creatinine I-NonOSE_AE
( O
12 O
% O
vs O
. O
7 O
% O
) O
, O
urea O
( O
20 O
% O
vs O
. O
12 O
% O
) O
, O
and O
hemoglobin O
( O
13 O
% O
vs O
. O
9 O
% O
) O
, O
but O
no O
difference O
in O
elevation B-NonOSE_AE
of I-NonOSE_AE
liver I-NonOSE_AE
transaminases I-NonOSE_AE
. O

Table O
2 O
lists O
all O
adverse O
reactions O
occurring O
in O
> O
=1 O
% O
of O
patients O
receiving O
PENNSAID O
1.5 O
% O
, O
where O
the O
rate O
in O
the O
PENNSAID O
1.5 O
% O
group O
exceeded O
placebo O
, O
from O
seven O
controlled O
studies O
conducted O
in O
patients O
with O
osteoarthritis B-Not_AE_Candidate
. O

Since O
these O
trials O
were O
of O
different O
durations O
, O
these O
percentages O
do O
not O
capture O
cumulative O
rates O
of O
occurrence O
. O

Table O
2 O
: O
Adverse O
Reactions O
Occurring O
in O
> O
=1 O
% O
of O
Patients O
Treated O
with O
PENNSAID O
1.5 O
% O
Topical O
Solution O
in O
Placebo O
and O
Oral O
Diclofenac-Controlled O
Trials O
Treatment O
Group O
: O
PENNSAID O
1.5 O
% O
N=911 O
Topical O
PlaceboN=332 O
Adverse O
Reaction O
N O
( O
% O
) O
N O
( O
% O
) O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
292 O
( O
32 O
) O
17 O
( O
5 O
) O
Contact B-OSE_Labeled_AE
Dermatitis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
83 O
( O
9 O
) O
6 O
( O
2 O
) O
Dyspepsia B-OSE_Labeled_AE
72 O
( O
8 O
) O
13 O
( O
4 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
54 O
( O
6 O
) O
10 O
( O
3 O
) O
Flatulence B-OSE_Labeled_AE
35 O
( O
4 O
) O
1 O
( O
< O
1 O
) O
Pruritus B-OSE_Labeled_AE
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
34 O
( O
4 O
) O
7 O
( O
2 O
) O
Diarrhea B-OSE_Labeled_AE
33 O
( O
4 O
) O
7 O
( O
2 O
) O
Nausea B-OSE_Labeled_AE
33 O
( O
4 O
) O
3 O
( O
1 O
) O
Pharyngitis B-OSE_Labeled_AE
40 O
( O
4 O
) O
13 O
( O
4 O
) O
Constipation B-OSE_Labeled_AE
29 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
Edema B-OSE_Labeled_AE
26 O
( O
3 O
) O
0 O
Rash B-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
25 O
( O
3 O
) O
5 O
( O
2 O
) O
Infection B-OSE_Labeled_AE
25 O
( O
3 O
) O
8 O
( O
2 O
) O
Ecchymosis B-OSE_Labeled_AE
19 O
( O
2 O
) O
1 O
( O
< O
1 O
) O
Dry B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
19 O
( O
2 O
) O
1 O
( O
< O
1 O
) O
Contact B-OSE_Labeled_AE
Dermatitis I-OSE_Labeled_AE
, O
vesicles O
( I-OSE_Labeled_AE
Application I-OSE_Labeled_AE
Site I-OSE_Labeled_AE
) O
18 O
( O
2 O
) O
0 O
Paresthesia B-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
14 O
( O
2 O
) O
3 O
( O
< O
1 O
) O
Accidental B-NonOSE_AE
Injury I-NonOSE_AE
22 O
( O
2 O
) O
7 O
( O
2 O
) O
Pruritus B-OSE_Labeled_AE
( O
Non-Application O
Site O
) O
15 O
( O
2 O
) O
2 O
( O
< O
1 O
) O
Sinusitis B-OSE_Labeled_AE
10 O
( O
1 O
) O
2 O
( O
< O
1 O
) O
Halitosis B-OSE_Labeled_AE
11 O
( O
1 O
) O
1 O
( O
< O
1 O
) O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Reaction I-OSE_Labeled_AE
( O
not O
otherwise O
specified O
) O
11 O
( O
1 O
) O
3 O
( O
< O
1 O
) O
6.2 O
Postmarketing O
Experience O
In O
postmarketing O
surveillance O
, O
the O
following O
adverse O
reactions O
have O
been O
reported O
during O
post- O
approval O
use O
of O
PENNSAID O
1.5 O
% O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
accidental B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
body B-OSE_Labeled_AE
odor I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
halitosis B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
: O
palpitation B-OSE_Labeled_AE
, O
cardiovascular B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
: O
diarrhea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
lip B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
ulcerative B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
swollen B-OSE_Labeled_AE
tongue I-OSE_Labeled_AE
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
: O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
: O
depression B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
drowsiness B-OSE_Labeled_AE
, O
lethargy B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
at I-OSE_Labeled_AE
application I-OSE_Labeled_AE
site I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
: O
asthma B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
laryngismus B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
throat B-OSE_Labeled_AE
swelling I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
At O
the O
Application B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
: O
rash I-OSE_Labeled_AE
, O
skin O
burning O
sensation O
; O
Other B-NonOSE_AE
Skin I-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Adverse I-NonOSE_AE
Reactions I-NonOSE_AE
: O
eczema B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
cataract B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
Vascular B-NonOSE_AE
: O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE

